Triple Therapy of Umeclidinium + Inhaled Corticosteroids/Long-Acting Beta2 Agonists for Patients with COPD: Pooled Results of Randomized Placebo-Controlled Trials

Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis

“…Nonetheless, as in the parent study, a statistically significantly greater reduction in the need for supplemental rescue bronchodilator medication (a clinical endpoint indicative of treatment effect on symptoms [36]) when patients were treated with UMEC/VI versus TIO/ OLO was also demonstrated in the MN subgroup. Again, the magnitude of this treatment difference was similar to that observed in the ITT population, and comparable to that reported with LAMA monotherapy versus placebo across multiple clinical trials [37,38]. However, there were no statistically significant betweentreatment differences in the questionnairebased CAT score or E-RS COPD total score at week 8.…”

“…Nevertheless, a numerical difference in the CAT responder analysis was seen at week 8, with 47% of UMEC/VI-treated patients compared with 38% of TIO/OLO-treated patients obtaining clinically relevant improvements in symptoms and health-related QoL, with a similar response rate at week 4, in line with the primary study. This magnitude of improvement in symptom burden and QoL is consistent with treatment benefit on CAT and other patientreported outcomes seen on escalating therapy from one to two bronchodilators in patients with more advanced COPD [37,39,40].…”

Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting

“…TT has been associated with good clinical and health outcomes in patients with COPD. For example, a post hoc analysis of four randomized trials in patients with symptomatic COPD demonstrated that the addition of UMEC as an add-on therapy to ICS/LABA for 12 weeks was associated with significant improvements in lung function, health status, and exacerbation risk compared with placebo plus ICS/LABA [10]. Improvements in health status were also observed at 12 weeks, as measured by COPD assessment test and St Georges Respiratory Questionnaire, compared with baseline [11].…”

FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease

“…In a US study, 25.5% of patients with COPD, who had received at least one LAMA, LABA, ICS, or phosphodiesterase-4 inhibitor, received triple therapy within 2 years of being diagnosed (2) 4 advanced, symptomatic COPD, who are at risk of exacerbations. It was designed in part to support the registration of once-daily FF/UMEC/VI in Europe and other countries globally.…”